Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the seventeen research firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $48.17.
Several analysts have commented on the stock. Wall Street Zen lowered shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Zacks Research downgraded Tango Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 27th. William Blair initiated coverage on Tango Therapeutics in a research report on Friday, October 16th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. raised their target price on Tango Therapeutics from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 10th. Finally, Stifel Nicolaus set a $55.00 target price on Tango Therapeutics in a research note on Friday, October 23rd.
View Our Latest Research Report on Tango Therapeutics
Insiders Place Their Bets
In other news, insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $24.47, for a total transaction of $660,690.00. Following the sale, the insider owned 115,743 shares in the company, valued at approximately $2,832,231.21. The trade was a 18.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jessica Newcomb sold 8,200 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00. Following the sale, the insider owned 59,121 shares in the company, valued at approximately $1,431,910.62. This trade represents a 12.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 52,231 shares of company stock valued at $1,254,029. 6.50% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of TNGX. Nykredit A S bought a new stake in Tango Therapeutics in the second quarter worth $26,000. Allworth Financial LP purchased a new stake in shares of Tango Therapeutics in the second quarter worth $35,000. Sterling Capital Management LLC grew its stake in shares of Tango Therapeutics by 838.8% in the third quarter. Sterling Capital Management LLC now owns 4,647 shares of the company’s stock worth $116,000 after acquiring an additional 4,152 shares during the last quarter. Global Retirement Partners LLC bought a new position in shares of Tango Therapeutics during the second quarter valued at $122,000. Finally, State of Wyoming bought a new position in shares of Tango Therapeutics during the first quarter valued at $128,000. 78.99% of the stock is currently owned by institutional investors.
Tango Therapeutics Trading Down 8.5%
Shares of NASDAQ TNGX opened at $22.11 on Wednesday. The firm has a fifty day simple moving average of $23.55 and a two-hundred day simple moving average of $22.91. Tango Therapeutics has a 12 month low of $7.69 and a 12 month high of $34.39. The firm has a market capitalization of $3.75 billion, a PE ratio of -16.14 and a beta of 1.26.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). On average, sell-side analysts predict that Tango Therapeutics will post -1.46 earnings per share for the current year.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
Further Reading
- Five stocks we like better than Tango Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
